Journal
VACCINE
Volume 35, Issue 9, Pages 1200-1201Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2016.10.070
Keywords
Dengue virus; Dengue vaccine; CYD-TDV; WHO vaccine position paper; Dengue; Dengvaxia (R); Recombinant tetravalent dengue vaccine
Categories
Funding
- World Health Organization [001] Funding Source: Medline
Ask authors/readers for more resources
This article presents the World Health Organization's (WHO) recommendations on the use of dengue vaccine excerpted from the WHO position paper on dengue vaccine published in the Weekly epidemiological Record in July 2016 (Dengue vaccine: WHO position paper, 2016) [1]. The current document is the first WHO position paper on dengue vaccination and focuses primarily on the available evidence concerning the only dengue vaccine to have been registered by National Regulatory Authorities. The position paper gives consideration to the epidemiological features of the disease and assesses the potential use of the vaccine for public health benefits. Footnotes to this paper provide a number of core references including references to grading tables that assess the quality of the scientific evidence, and to the evidence -to -recommendation table. In accordance with its mandate to provide guidance to Member States on health policy matters, WHO issues a series of regularly updated position papers on vaccines and combinations of vaccines against diseases that have an international public health impact. These papers are concerned primarily with the use of vaccines in large-scale immunization programmes; they summarize essential background information on diseases and vaccines, and conclude with WHO's current position on the use of vaccines in the global context. This paper reflects the recommendations of the WHO's Strategic Advisory Group of Experts (SAGE) on immunization. (C) 2016 Elsevier Ltd. All rights reserved.
Reviews
Recommended
No Data Available